Cargando…

Phosphoramidate Prodrugs Continue to Deliver, The Journey of Remdesivir (GS-5734) from RSV to SARS-CoV-2

[Image: see text] Remdesivir (GS-5734) is a monophenol, 2-ethylbutylalanine phosphoramidate prodrug of a 1′-cyano-4-aza-7,9-dideazaadenosine C-nucleoside (GS-441524) that is FDA approved for the treatment of hospitalized patients with COVID-19. The prodrug, initially invented for respiratory syncyti...

Descripción completa

Detalles Bibliográficos
Autor principal:	Mackman, Richard L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Chemical Society 2022
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8887656/ https://www.ncbi.nlm.nih.gov/pubmed/35291757 http://dx.doi.org/10.1021/acsmedchemlett.1c00624

Ejemplares similares

Coronavirus Susceptibility to the Antiviral Remdesivir (GS-5734) Is Mediated by the Viral Polymerase and the Proofreading Exoribonuclease
por: Agostini, Maria L., et al.
Publicado: (2018)

Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection
por: de Wit, Emmie, et al.
Publicado: (2020)

Current knowledge about the antivirals remdesivir (GS-5734) and GS-441524 as therapeutic options for coronaviruses
por: Amirian, E. Susan, et al.
Publicado: (2020)

Remdesivir (GS-5734) Impedes Enterovirus Replication Through Viral RNA Synthesis Inhibition
por: Ye, Wei, et al.
Publicado: (2020)

Recent knowledge in favor of remdesivir (GS-5734) as a therapeutic option for the COVID-19 infections
por: Saqrane, S., et al.
Publicado: (2021)

Corrigendum: Remdesivir (GS-5734) Impedes Enterovirus Replication Through Viral RNA Synthesis Inhibition
por: Ye, Wei, et al.
Publicado: (2020)

Oral prodrug of remdesivir parent GS-441524 is efficacious against SARS-CoV-2 in ferrets
por: Cox, Robert M., et al.
Publicado: (2021)

GS-5734 and its parent nucleoside analog inhibit Filo-, Pneumo-, and Paramyxoviruses
por: Lo, Michael K., et al.
Publicado: (2017)

Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys
por: Warren, Travis K., et al.
Publicado: (2016)

The Potential Protective Role of GS-441524, a Metabolite of the Prodrug Remdesivir, in Vaccine Breakthrough SARS-CoV-2 Infections
por: Zhu, JiaYi, et al.
Publicado: (2022)

Evidence for the Effectiveness of Remdesivir (GS-5734), a Nucleoside-Analog Antiviral Drug in the Inhibition of I (K(M)) or I (K(DR)) and in the Stimulation of I (MEP)
por: Chang, Wei-Ting, et al.
Publicado: (2020)

Synthetic Approaches for the Preparation of Phosphoramidate Prodrugs of 2′‐Deoxypseudoisocytidine
por: Serpi, Michaela, et al.
Publicado: (2017)

Broad-spectrum Investigational Agent GS-5734 for the Treatment of Ebola, MERS Coronavirus and Other Pathogenic Viral Infections with High Outbreak Potential
por: Jordan, Robert, et al.
Publicado: (2017)

Efficacy of the oral nucleoside prodrug GS-5245 (Obeldesivir) against SARS-CoV-2 and coronaviruses with pandemic potential
por: Martinez, David R., et al.
Publicado: (2023)

Therapeutic treatment with an oral prodrug of the remdesivir parental nucleoside is protective against SARS-CoV-2 pathogenesis in mice
por: Schäfer, Alexandra, et al.
Publicado: (2022)

Structural Insights into Plasticity and Discovery of Remdesivir Metabolite GS-441524 Binding in SARS-CoV-2 Macrodomain
por: Ni, Xiaomin, et al.
Publicado: (2021)

A mild and concise synthesis of aryloxy phosphoramidate prodrug of alcohols via transesterification reaction
por: Ying, Hanglu, et al.
Publicado: (2022)

Remdesivir and GS-441524 Retain Antiviral Activity against Delta, Omicron, and Other Emergent SARS-CoV-2 Variants
por: Pitts, Jared, et al.
Publicado: (2022)

Co-administration of Favipiravir and the Remdesivir Metabolite GS-441524 Effectively Reduces SARS-CoV-2 Replication in the Lungs of the Syrian Hamster Model
por: Chiba, Shiho, et al.
Publicado: (2022)

Metabolic Efficacy of Phosphate Prodrugs and the Remdesivir Paradigm
por: Wiemer, Andrew J.
Publicado: (2020)

Practical and Highly Efficient Synthesis of Remdesivir from GS-441524
por: Hu, Tianwen, et al.
Publicado: (2022)

Broad-spectrum in vitro antiviral activity of ODBG-P-RVn: an orally-available, lipid-modified monophosphate prodrug of remdesivir parent nucleoside (GS-441524)
por: Lo, Michael K., et al.
Publicado: (2021)

Broad-Spectrum In Vitro Antiviral Activity of ODBG-P-RVn: An Orally-Available, Lipid-Modified Monophosphate Prodrug of Remdesivir Parent Nucleoside (GS-441524)
por: Lo, Michael K., et al.
Publicado: (2021)

Phosphoramidates of 2′-β-d-arabinouridine (AraU) as phosphate prodrugs; design, synthesis, in vitro activity and metabolism
por: Mehellou, Youcef, et al.
Publicado: (2010)

Combination of the parent analogue of remdesivir (GS-441524) and molnupiravir results in a markedly potent antiviral effect in SARS-CoV-2 infected Syrian hamsters
por: Abdelnabi, Rana, et al.
Publicado: (2022)

An efficient synthesis of RNA containing GS-441524: the nucleoside precursor of remdesivir
por: Moorthy, Ramkumar, et al.
Publicado: (2021)

Population Pharmacokinetics of Remdesivir and GS-441524 in Hospitalized COVID-19 Patients
por: Leegwater, E., et al.
Publicado: (2022)

Transplacental transfer of Remdesivir and GS‐441524: An ex vivo perfusion study
por: Louchet, Margaux, et al.
Publicado: (2023)

The journey of remdesivir: from Ebola to COVID-19
por: Pardo, Joe, et al.
Publicado: (2020)

Intravenous delivery of GS-441524 is efficacious in the African green monkey model of SARS-CoV-2 infection
por: Pitts, Jared, et al.
Publicado: (2022)

Discovery of a 2′-Fluoro,2′-Bromouridine Phosphoramidate Prodrug Exhibiting Anti-Yellow Fever Virus Activity in Culture and in Mice
por: LeCher, Julia C., et al.
Publicado: (2022)

Advantages of the Parent Nucleoside GS-441524 over Remdesivir for Covid-19 Treatment
por: Yan, Victoria C., et al.
Publicado: (2020)

Subcutaneous remdesivir administration prevents interstitial pneumonia in rhesus macaques inoculated with SARS-CoV-2
por: Williamson, Brandi N., et al.
Publicado: (2022)

Assessment of Purity, Stability, and Pharmacokinetics of NGP-1, a Novel Prodrug of GS441254 with Potential Anti-SARS-CoV-2 Activity, Using Liquid Chromatography
por: Sun, Chen, et al.
Publicado: (2023)

Therapeutic Efficacy and Outcomes of Remdesivir versus Remdesivir with Tocilizumab in Severe SARS-CoV-2 Infection
por: Vulturar, Damiana-Maria, et al.
Publicado: (2022)

Early experience with remdesivir in SARS-CoV-2 pneumonia
por: Durante-Mangoni, Emanuele, et al.
Publicado: (2020)

Contre Sars-CoV-2, brequinar ou remdesivir ?
por: Manus, Jean-Marie
Publicado: (2021)

Remdesivir therapy associated with Bradycardia in SARS‐CoV2
por: Kumar, Sabina, et al.
Publicado: (2021)

Mechanism of SARS-CoV-2 polymerase stalling by remdesivir
por: Kokic, Goran, et al.
Publicado: (2021)

Enhanced Remdesivir Analogues to Target SARS-CoV-2
por: Majima, Ryuichi, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_5onb41s5hd8rdljku7oa0npi07